Stocks of Amyris Inc. (NASDAQ:AMRS) traded higher last session on Wall Street, down -24.20% to $0.45.
According to the data, Amyris Inc. (NASDAQ:AMRS) has 8 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $0.70, we find $1.13. Given the previous closing price of $0.60, this indicates a potential upside of 88.33 percent. AMRS stock price is now -54.19% away from the 50-day moving average and -67.41% away from the 200-day moving average. The market capitalization of the company currently stands at $175.84M.
A total of 5 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $1.71 as their price target over the next twelve months.
With the price target reduced from $3.10 to $0.65, Jefferies Downgraded its rating from Buy to Hold for Amyris Inc. (NASDAQ: AMRS).
In other news, Kieftenbeld Hermanus, CHIEF FINANCIAL OFFICER sold 20,999 shares of the company’s stock on Jun 02. The stock was sold for $19,949 at an average price of $0.95. Upon completion of the transaction, the CHIEF FINANCIAL OFFICER now directly owns 219,768 shares in the company, valued at $98895.6. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 05, CHIEF OPERATING OFFICER ALVAREZ EDUARDO sold 231,368 shares of the business’s stock. A total of $284,305 was realized by selling the stock at an average price of $1.23. This leaves the insider owning 612,546 shares of the company worth $0.28 million. Insiders disposed of 1,525,386 shares of company stock worth roughly $0.69 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AMRS stock. A new stake in Amyris Inc. shares was purchased by CALAMOS WEALTH MANAGEMENT LLC during the first quarter worth $271,000. AXS INVESTMENTS LLC invested $219,000 in shares of AMRS during the first quarter. In the first quarter, HARBOR CAPITAL ADVISORS, INC. acquired a new stake in Amyris Inc. valued at approximately $63,000. INTEGRATED WEALTH CONCEPTS LLC acquired a new stake in AMRS for approximately $48,000. MARINER INDEPENDENT ADVISOR NETWORK, LLC purchased a new stake in AMRS valued at around $47,000 in the second quarter. In total, there are 221 active investors with 38.90% ownership of the company’s stock.
During the past 12 months, Amyris Inc. has had a low of $0.55 and a high of $4.86. The fifty day moving average price for AMRS is $0.9824 and a two-hundred day moving average price translates $1.3778 for the stock.
The latest earnings results from Amyris Inc. (NASDAQ: AMRS) was released for Mar, 2023. According to the Specialty Chemicals Company, earnings per share came in at -$0.33, missing analysts’ expectations of -$0.32 by -0.01. This compares to -$0.34 EPS in the same period last year. The company reported revenue of $56.08 million for the quarter, compared to $57.71 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.82 percent. For the current quarter, analysts expect AMRS to generate $276.93M in revenue.
Amyris Inc.(AMRS) Company Profile
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
